Oncorus Secures $57M Via Equity At 9% Discount

• Oncorus Inc (NASDAQ: ONCR) prices of its underwritten public offering of 3 million common shares at $19 per share, raising $57 million in gross proceeds. The offer price represents a discount of 9% on the last close price of $20.97 on Thursday.

• Underwriters have an option to purchase up to an additional 450,000 shares. The offering is expected to close on February 17

• Jefferies, Evercore ISI, and Piper Sandler are acting as joint book-running managers for the offering.

• Last month, Oncorus announced preclinical data for ONCR-177 that demonstrated potent and durable antitumor activity in multiple immune-competent tumor models.

• Oncorus also announced building a viral immunotherapy clinical manufacturing facility in the U.S., with full operation commencing in early 2023.

• Price Action: ONCR dipped 11.1% at $17.8 on the last check Friday.

See more from Benzinga

• Click here for options trades from Benzinga

• Denali's Enzyme Replacement Therapy Shows Encouraging Biomarker Effects In Early-Stage Hunter Syndrome Study

• Becton, Dickinson's COVID-19/Influenza Combo Molecular Assay Wins FDA Emergency Use Nod

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.